Obsidian Therapeutics Company
Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy.
Investors
Technology:
Cell-based gene therapy
Industry:
Gene therapy, Private
Headquarters:
Cambridge, Massachusetts, United States
Founded Date:
2015-01-01
Employees Number:
51-100
Funding Status:
Early Stage Venture
Investors Number:
18
Total Funding:
164500000
Estimated Revenue:
$1M to $10M
Last Funding Date:
2021-09-09
Last Funding Type:
Series B
Register and Claim Ownership